Dr Lal PathLabs a well recognised brand in the Diagnostic Sector

If Lal Pathlab pays the same to acquire Dr Lal Chandani Labs ( Moat - lab in premium locations in Delhi) i.e, 18x EBITA then Lal Chandani should be trading around 36 cr Mcap based on FY21 EBITA of 2 cr. ( its trading at 10 cr Mcap )

I think for larger players to grow they have acquire good , establish smaller players who have local advantage due their establishment in 1980s like in case of Dr lal chandani.

Lal Chandani is interesting play -
they got approvals for Announcement Regarding Approval For COVID-19 Vaccination Centre.

[Increased the Capacity For Covid-19 RT-PCR Testing.]

(https://www.bseindia.com/xml-data/corpfiling/AttachHis/15d52f5c-62fa-4ed9-8f14-36cbca4f9b3f.pdf)

Totally IT enabled and Motivated promoter - trying to expand outside delhi -

Linkdin profile snapshot -

Post IPO they have used the funds for enabling IT infra, opening 4-5 more labs and collection centres , i think this half-yearly we will see the fruits of it.

Created a topic on this company Dr Lal Chandani Labs

2 Likes